In a 20-patient Phase 1 clinical trial of ALD-201, the product candidate was well-tolerated and the trial provided initial evidence of improved blood flow and improved clinical status. The results showed a statistically significant reduction in ischemia in the ALD-201 treatment group as compared to a placebo group. In addition, after six months, the ALD-201 treatment group had a greater improvement in MaxVO2, a customary measure of the body’s ability to take up oxygen during exercise, than did the placebo group.
